Navigation Links
New study aims to improve long-term treatment for patients with bipolar disorder
Date:5/24/2011

NEW YORK (May 23, 2011) -- Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications -- quetiapine (Seroquel), a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.

NewYork-Presbyterian Hospital/Weill Cornell Medical Center is one of 10 sites nationally -- and the only site in the greater New York metropolitan area -- participating in the CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness) study. The research is funded by a $10 million grant from the U.S. Agency for Healthcare Research Quality (AHRQ).

"Antipsychotic drugs have long been known to be useful for the treatment of bipolar disorder, but neurological side effects and toxicity have limited their long-term use. The good news is that the newer-generation antipsychotic drugs like quetiapine appear to be effective while having fewer neurological side effects," says Dr. James H. Kocsis, site principal investigator, director of the Payne Whitney Affective Disorders Research Clinic at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and professor of psychiatry at Weill Cornell Medical College. "In this context, it is important that we compare the relative utility of the old-fashioned mood stabilizers like lithium and the newer second-generation antipsychotic drugs -- with the ultimate goal of improving long-term treatment for patients with bipolar disorder."

Researchers will follow 480 patients with bipolar disorder randomized to one of the two medications over a six-month period. Participants can continue taking other prescriptions, such as antidepressants, as long as they are not antipsychotic drugs. Often patients with bipolar disorder need three medications to feel well, explains Dr. Kocsis.

Bipolar disorder is a lifelong, chronic and highly recurrent mood disorder characterized by episodes of mania that alternate with episodes of major depression. Symptoms can negatively affect personal relationships, job or school performance, and may result in suicide.

The study is coordinated through the Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program. The lead principal investigator is Dr. Andrew A. Nierenberg, director of the MGH Bipolar Research Program.

The AHRQ grant is part of an investment made under the American Recovery and Reinvestment Act of 2009, which designated $1.1 billion to support patient-centered outcomes research. This research is designed to inform health care decisions by providing evidence and information on the effectiveness, benefits and harms of different treatment options.


'/>"/>

Contact: Takla Boujaoude
tab2016@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Medicare improved Canadian doctors salaries: Queens University study
2. IUPUI study first to look at early treatment of depression to reduce heart disease risk
3. A Cultured Man Is a Healthier, Happier Man: Study
4. New study finds that violence doesnt add to childrens enjoyment of TV shows, movies
5. UTMB researcher receives $3 million NIH grant to study aging in Mexico
6. Study finds patient navigation increases colorectal cancer screening in ethnically diverse patients
7. Study links acetaminophen to lower prostate cancer risk
8. Some Dentists Reluctant to Treat Kids on Medicaid: Study
9. Younger Docs More Likely to Prescribe Drugs for Heart Disease: Study
10. Common test could help predict early death in diabetes, study shows
11. Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology: